TL;DR
The FDA approved the first generic version of the once-weekly estradiol-levonorgestrel patch, indicated for moderate to severe vasomotor symptoms and osteoporosis prevention in postmenopausal women with an intact uterus. The patch has specified contraindications and a boxed warning; the agency has also announced plans to remove boxed warnings from some menopause hormone therapies, but the source does not say whether that change applies to this product or when.
The U.S. Food and Drug Administration on Monday approved the first generic version of a once-weekly estradiol and levonorgestrel patch, a hormone therapy indicated for moderate to severe menopausal hot flashes and prevention of osteoporosis in postmenopausal women with an intact uterus. The approval adds a generic option to a treatment category where clinicians and patients must weigh symptom relief against significant prescribing warnings and individual health risks.
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The transdermal system is the generic of Climara Pro and delivers daily doses of 0.045 milligrams of estradiol and 0.015 milligrams of levonorgestrel. Although applied once a week, the patch supplies those hormones daily. The FDA indication described in the report covers moderate to severe vasomotor symptoms and osteoporosis prevention in the specified postmenopausal population.
Levonorgestrel is a progestogen. The FDA said it is included to reduce the risk of endometrial hyperplasia, a thickening of the uterine lining that can occur with estrogen use alone. The agency’s statement described weekly dosing as an alternative to daily oral medication. It did not provide a price, manufacturer, expected retail availability date, or evidence that this generic will cost less than the brand product.
The label lists common adverse events reported in at least 5% of users, including application-site reactions and vaginal bleeding, as well as upper respiratory infection, breast, back or general pain, depression, headache and flu-like symptoms. The product is contraindicated for people with certain conditions, including unexplained abnormal genital bleeding, known or suspected breast cancer, active blood clots, liver impairment and specified thrombophilic disorders.
A New Generic, With Existing Risks
The approval adds a generic option for a weekly combination patch, which may broaden choices for eligible patients who need both estrogen and a progestogen. The once-weekly schedule differs from daily oral medication, but the FDA’s statement that it may help patients stay on track is a rationale for the format, not evidence in the source that adherence will improve for every user.
The decision does not remove the need for individualized prescribing. The product’s label carries a boxed warning about cardiovascular disorders, probable dementia, breast cancer and endometrial cancer, based on findings from the Women’s Health Initiative, and lists conditions that rule out use. Patients considering hormone therapy need to discuss personal risks and alternatives with a clinician; the source does not establish that the generic changes the therapy’s underlying risk profile.
Products Worth Considering
Therabody WaveRoller Vibrating Foam Roller
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms, White
Garmin Fenix 8 47 mm AMOLED Sapphire Multisport GPS Smartwatch with Titanium Case and Silicone Band
As an affiliate, we earn on qualifying purchases.
How the Patch Combines Hormones
Climara Pro combines estradiol, an estrogen, with levonorgestrel, a progestogen, in a patch applied once weekly. The approval described in the report is for its first generic counterpart, not a new hormone combination or a new indication. Its specified use is for postmenopausal women with an intact uterus.
The report notes that the approval follows recent endorsements from the American College of Obstetricians and Gynecologists and the American College of Physicians concerning treatment of menopausal symptoms. It does not provide details of those endorsements or say they specifically recommend this patch. Separately, the FDA recently announced plans to remove boxed warnings from a number of hormone therapy products used for menopausal symptoms. The report does not clarify whether or when that planned action will affect this patch’s labeling.
“Once-weekly dosing can make a real difference in how patients manage their care.”
— Michael Davis, MD, PhD, director of the FDA’s Center for Drug Evaluation and Research
Label Changes and Availability Pending
The source does not identify the generic’s manufacturer, price, pharmacy availability or launch date. It also does not provide clinical trial results comparing the generic with Climara Pro, or evidence about whether its use changes adherence or patient outcomes.
The report says the FDA plans to remove boxed warnings from a number of hormone therapy products, but does not specify whether this particular product is included, what the revised wording would be, or when any label change might take effect. Until a change is confirmed for this product, the reported prescribing information still includes the boxed warning and listed contraindications.
Watch for Label and Market Details
Further details to watch for include when the generic becomes available, which company will supply it and whether its price differs from the brand product. Patients should consult the current prescribing information and a health professional before starting or changing hormone therapy, particularly if they have a condition listed among the contraindications.
Any change to the patch’s boxed warning would depend on subsequent FDA action and product labeling. The approval announcement alone does not establish that the warning has been removed or that the product’s approved uses have changed.
Key Questions
What did the FDA approve?
The FDA approved the first generic version of the once-weekly estradiol-levonorgestrel transdermal system, a generic of Climara Pro, according to the report.
Who is the patch indicated for?
It is indicated for postmenopausal women with an intact uterus to treat moderate to severe vasomotor symptoms and prevent osteoporosis.
How often is the patch used?
The patch is applied once weekly. It delivers daily doses of 0.045 mg estradiol and 0.015 mg levonorgestrel.
Does the generic have the same boxed warning?
The report says the prescribing information carries a boxed warning about cardiovascular disorders, probable dementia, breast cancer and endometrial cancer. It also says the FDA plans to remove boxed warnings from some hormone therapy products, but does not confirm whether this patch is included or when its label might change.
When will the generic be available and how much will it cost?
The source does not give an availability date, manufacturer or price, so those details remain unknown.
Source: rss
